Premium
Somatostatin receptor expression in multiple endocrine neoplasia and in von hippel–lindau disease
Author(s) -
Lely A. J. V. D.
Publication year - 1998
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1046/j.1365-2796.1998.00340.x
Subject(s) - somatostatin receptor , somatostatin , somatostatin receptor 1 , medicine , endocrinology , somatostatin receptor 2 , von hippel–lindau disease , endocrine system , multiple endocrine neoplasia , receptor , multiple endocrine neoplasia type 2 , cancer research , lanreotide , neuroendocrine tumors , radionuclide therapy , pathology , hormone , acromegaly , disease , biology , growth hormone , germline mutation , mutation , gene , biochemistry
Lamberts SWJ, Hofland LJ, Lely AJVD, de Herder WW (Erasmus University Rotterdam, The Netherlands). Somatostatin receptor expression in multiple endocrine neoplasia and in von hippel– lindau disease (Minisymposium: MEN & VHL). J Intern Med 1998; 243 : 569–71. Somatostatin receptors are expressed on the majority of neuroendocrine tumours. The presence of these receptors is clinically useful. First, long‐term treatment with somatostatin analogues controls hormonal hypersecretion, which controls flushing attacks, watery diarrhoea, hypoglycaemia and electrolyte disorders in patients with carcinoids and islet cell tumours. Secondly, somatostatin receptor imaging is used to localize primary neuroendocrine tumours and to visualize the spread of the disease. Thirdly internalization of somatostatin receptors by primary neuroendocrine tumours opens the possibility of carrying out radio‐ and chemotherapy with somatostatin analogues coupled to beta‐emitting radionuclides and chemotherapeutic drugs. The presence and role of somatostatin receptors on the tumours which occur in multiple endocrine neoplasia and von Hippel–Lindau disease are discussed.